frica hosts fewer than 2% of global clinical trials despite carrying nearly a quarter of global disease burden. A major driver of this gap is regulatory fragmentation, with more than 40 national regulatory authorities operating at different maturity levels. Multicountry studies often face duplicative reviews, adding 60–90 days even under African Vaccine Regulatory Forum (AVAREF) joint reviews compared with 6–12 months individually.

South Africa’s Role in Advancing Convergence

South Africa occupies a distinctive place in this landscape. Through the South African Health Products Regulatory Authority (SAHPRA), the country has developed one of the continent’s most mature regulatory systems. In 2022, the World Health Organization (WHO) assessed SAHPRA’s vaccine regulatory system at Maturity Level 3, indicating a stable and functional oversight system. This outcome matters not only for South Africa but also for the wider region, because stronger national systems make reliance, collaboration, and cross-border confidence more feasible.

SAHPRA participates in African Union Development Agency-New Partnership for Africa’s Development (AUDA-NEPAD) initiatives, contributes to AVAREF joint reviews, and supports Southern African Development Community (SADC) harmonization efforts. Its modernization, including electronic submissions, reliance pathways, and alignment with WHO Listed Authority frameworks, directly supports AMA’s mandate.

Why South Africa Matters in African Clinical Research

South Africa’s high disease burden, strong clinical-research infrastructure, and alignment with global clinical trial guidelines position it as a continental anchor for high-quality research. Examples include:

• Operationalization of the electronic Clinical Trial Application Platform (eCTAP)
• Consistent adoption of ICH-aligned clinical trial guidelines
• Reliable ethics and regulatory systems enabling rapid trial activation.

South Africa’s leadership is evident in major multicountry trials:

• HIV Vaccine Trials: In early 2026, the BRILLIANT 011 first-in-human HIV vaccine trial launched in Cape Town, led by the South African Medical Research Council (SAMRC) and the BRILLIANT Consortium. This African-led study is testing a novel vaccine targeting conserved HIV regions to strengthen T-cell responses in 20 HIV-negative volunteers. Its rapid initiation reflects coordinated regulatory and ethics reviews aligned with AVAREF’s joint review model.
• Tuberculosis Vaccine Oversight: AVAREF’s harmonized review processes have strengthened oversight for TB vaccine evaluations across the continent, including South Africa’s major role in the ongoing M72/AS01E phase 3 trial (2025 enrollment completed early across South Africa, Kenya, Malawi, Zambia, and Indonesia).
• COVID-19 Vaccine Trials: During the COVID-19 pandemic, AVAREF’s joint review model enabled rapid, coordinated assessment of vaccine trial protocols across multiple African countries, improving speed and consistency of regulatory decisions.
• KEYNOTE-522 oncology trial participation: 522 demonstrated that pembrolizumab plus chemotherapy improved event‑free and overall survival in triple‑negative breast cancer, with South Africa participating as one of the global trial sites, reflecting the country’s capacity to contribute to complex, multicountry oncology studies.
• SOUL and RIC-AFRICA cardiovascular and diabetes trials: Large multicountry noncommunicable disease (NCD) trials also rely on harmonized African regulatory processes, including the SOUL cardiovascular-outcomes trial of semaglutide (across Africa, Europe, and Asia) and the RIC-AFRICA trial, which enrolled ~1,400 myocardial-infarction patients across seven African countries to evaluate remote ischemic conditioning.

These examples demonstrate how harmonized processes and reliance models accelerate high-impact research across Africa.

Digital Health Technologies and Data Governance

Digital health technologies (DHTs) are reshaping trial conduct across Africa. South Africa has seen rapid adoption of:

• Telemedicine for remote follow-up
• Wearable sensors for continuous monitoring
• Mobile platforms for data capture
• AI-enabled tools for recruitment and analytics

These innovations align with FDA’s Digital Health Framework, EMA guidance on digital technologies, and the International Council for Harmonization (ICH) E6(R3) and E8(R1) principles emphasizing data integrity, patient-centricity, and risk-based oversight.

Global experience, including the General Data Protection Regulation (GDPR), inspired governance, and South Africa’s Protection of Personal Information Act (POPIA) shows that privacy-preserving, audit-ready data systems strengthen regulatory oversight by enabling traceability, transparency, and continuous monitoring of processing activities.

Digital tools reduce site burden, expand access to rural populations, and improve retention—critical for multicountry oncology, vaccine, and NCD trials.

The Role of TCIS Africa 2026

The TCIS Africa Summit provides a neutral, continental platform to advance regulatory convergence, strengthen reliance pathways, and accelerate AMA implementation. Its 2026 focus on quality, trust, and digital transformation supports shared review models; strengthened pharmacovigilance; digital health regulatory frameworks; and cross-border collaboration among regulators, sponsors, and investigators.

By building on South Africa’s leadership and aligning with AMA and AVAREF, TCIS Africa can help create a more efficient, equitable, globally connected regulatory ecosystem.

Broader Implications

Regulatory harmonization has profound implications for patients, communities, and health systems. Faster, more predictable review processes enable earlier access to innovative therapies, particularly in areas of high disease burden such as oncology, HIV, tuberculosis, and NCDs. Harmonization also strengthens Africa’s global regulatory presence, enabling the continent to participate more fully in international regulatory science.

For industry, harmonization reduces operational complexity and encourages investment in multicountry trials. Digital health technologies further enhance trial efficiency, improve data quality, and expand access to underserved populations. Together, these developments position Africa as a competitive and attractive region for clinical research.

Path Forward for Africa’s Regulatory and Clinical Research Ecosystem

To realize the full potential of AMA, African regulators, policymakers, and industry leaders must accelerate harmonization efforts, expand reliance pathways, and invest in digital health infrastructure. Over the next two to three years, coordinated action is needed to strengthen regulatory capacity, align with global frameworks, and operationalize shared review models. The 2026 TCIS Africa Summit offers a critical opportunity to advance these goals, foster collaboration, and shape the future of African regulatory science.